Guide App, a Houston startup, is looking to help its users tap into social media better. Photo via Getty Images

Just look at any smartphone on the market and it becomes evident just how pervasive mobile apps have become, especially social media apps.

As the social networking sphere has revolutionized communication, technology has spawned multitudinous variants in the most organic way. That kind of technological momentum lends itself to why platforms like Guide App have a chance to be the next big thing in the space.

The company's CEO and co-founder, Tim Salau, tells InnovationMap that Guide is a social learning and development platform that aims to revolutionize learning experiences for creators, leaders, and organizations.

“Guide is a social learning platform for creators who are freelancers and work in the entertainment and media industry,” says Salau, Houston native and University of Texas graduate. “And they can use Guide to create and learn production skills. We pivoted in late 2019 as the pandemic hit, and we realized that Guide could be used as a B2B platform and solution for businesses to onboard and train their remote workers.

“So that's really what makes us money, and we really decided to build it because we saw that there was a huge gap in the business space of a bite-sized training platform and solution, and to do what TikTok and Reels was doing in the consumer space, but for professionals with security and privacy in mind for organizations,” he says.

With the pivot, businesses can now use Guide as a platform to onboard and train new hires for their respective companies.

“Ideally, it would be pretty much anyone within the marketing department, the product management division, or even engineers within their organizations who are creators in the sense of migrating to creative work in their own different disciplines,” says Salau. “And they could use Guide to potentially maybe create a video that's 90 seconds or less on everything a new hire needs to know within the first 90 days in the product management role or in the marketing role.”

Tapping into trends

Salau explains how he's got his ear to the ground when it comes to trends within media.

“With the way that things are moving in the entertainment and media industry and what's been happening with these strikes, I see the short-form content becoming even more important because people are not necessarily attending movie theaters at a high engagement rate,” says Salau. “Then there are multiple streaming platforms have so many gates and paywalls up, a lot of people aren't necessarily using all of these streaming platforms and seeing all of the long-form content out."

“I'm starting to see that in the next three to five years, macro content will become more important, and instead of the streaming era that we've seen in the last few years or in the last decade or so led by Netflix, I'm going to use our mock theory, we're going to start seeing a beaming era in which we're going to start seeing content being pushed to creators and consumers, that is literally tailored to what they want.”

According to Salau, platforms such as Instagram and TikTok push content based on their respective algorithms that followers don’t necessarily want to see, and that takes time away from the content they need, when they need it.

“Looking forward, it’s clear that in the sense of taking away all of the distractions that we see on these platforms, at Guide, we want to push content as it comes from the creators,” says Salau. “And for us, that focus will be on microcontent, which is content that’s 90 seconds or less.”

Data shows that the best micro content is video content that clocks in around 15 seconds.

“Content that goes up to 30 seconds is probably even cutting it a little bit too long, but the content that really goes a lot, and goes really viral on those platforms is 15 seconds,” says Salau. “And now that TikTok is becoming a more long-form entertainment platform, you're starting to see them kind of strip away from what really got them popular and buzzworthy.”

Monitoring monetization

Popularity aside, one of the major tenets of content creation is monetization.

“Getting to the point where creators will be able to monetize their content is our goal at Guide,” says Salau. “We have to build up towards that goal, but that’s the intent. We intend on having them be able to create profiles where they can actually list their merch. They can post about merch in their videos, and more importantly, get to a point where people can actually buy the entertaining content that they have.”

Once Guide reaches monetization, creators will be able to list content at the price they want it and have associated merchandise of their brand. This is a huge difference from how TikTok and Instagram and other consumer video platforms get creators paid.

“We see that it's better to actually go the other route and actually allow creators to monetize their own brand, which is what every creator often really wants,” says Salau. “That’s ideal because when a creator brings consumer brands into the picture, they have to play to what they want from an advertisement and dollars type of standpoint. So, we don't want to actually get into that world. We want to really keep everything creator oriented.”

Curating a culture of creators

At this point, Guide has about 150 creators, because they’ve been very selective with their icon program.

“We don’t believe that everyone’s a creator,” says Salau. “Because if everyone is a creator, then no one is a creator.

“And we kind of see this with a lot of the creator platforms out there. Just because anyone can create content with a smartphone doesn't mean it's content that's edifying or beneficial that people are actually enriching and learning from. So, we're really big on learning, because we see ourselves in that space.”

As Salau and team look forward with Guide, they plan on continuing to address the learning and talent development gap for remote and mobile teams. They’ll also remain focused on being the kind of platform where creators can talk about the behind-the-scenes and the process of how to make music or how to approach acting, or how to think about set production when on a set.

“With Instagram and TikTok, it’s really much more about fun and virality, and doing something that gets a reaction, versus helping people learn,” says Salau. “So, with us, the feedback we've received is, ‘I get it,’ and ‘I'm interested.’ And I want to continue learning and growing with y'all. Thank you.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.